NCT02289378.

Trial name or title	Dose‐dense biweekly docetaxel, oxaliplatin and 5‐fluorouracil as first‐line treatment in advanced gastric cancer (DaeMon‐Plus)
Methods	Phase 2 Intervention Model: Single‐group assignment Masking: Open‐label Primary Purpose: Treatment
Participants	N = 30 Age 18‐75 years · Participants with histologically or cytologically confirmed unresectable gastric adenocarcinoma whose ECOG performance status are 0‐2
Interventions	Experimental: docetaxel, oxaliplatin and 5‐Fu Docetaxel 50 mg/m² Oxaliplatin 85 mg/m² 5‐Fu 2800 mg/m² Repeated every two weeks
Outcomes	Progression‐free survival [Time frame: 2 years]
Starting date	November 2014
Contact information	Ping Lan, MD The Sixth Affilated Hospital of Sun Yat‐sen University
Notes